News and ViewsIs TransMedics Group, Inc. overvalued or undervalued?
2025-11-11 11:34:46As of 7 November 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22, which suggest that while the stock is not undervalued, it is also not excessively priced compared to its recent valuation history. In comparison to its peers, TransMedics has a significantly higher P/E ratio than CONMED Corp., which stands at 19.96, and a lower EV to EBITDA than Integer Holdings Corp. at 41.17. This indicates that while TransMedics may be on the higher end of the valuation spectrum, it still holds a competitive position within its industry. Notably, the stock has outperformed the S&P 500 with a year-to-date return of 96.30% compared to the S&P 500's 14.40%, reinforcing the notion that the market recognizes its growth poten...
Read MoreIs TransMedics Group, Inc. overvalued or undervalued?
2025-11-10 11:16:11As of 7 November 2025, the valuation grade for TransMedics Group, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22. In comparison to peers, TransMedics has a significantly higher P/E ratio than CONMED Corp. at 19.96 and Integer Holdings Corp. at 41.17, indicating a premium valuation relative to these companies. Additionally, the PEG ratio of 0.53 suggests that the stock may be undervalued in terms of its growth potential compared to its price. Although specific return data is not available, the absence of a return comparison with the S&P 500 does not detract from the overall assessment of fair valuation....
Read MoreIs TransMedics Group, Inc. overvalued or undervalued?
2025-11-09 11:09:46As of 7 November 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22. In comparison, peers such as CONMED Corp. have a more attractive P/E of 19.96, while Integer Holdings Corp. is considered very expensive with a P/E of 41.17. TransMedics has demonstrated strong performance with a year-to-date return of 91.13%, significantly outperforming the S&P 500's 14.40% during the same period. This performance, coupled with its fair valuation, suggests that while the stock is currently not undervalued, it has been able to deliver impressive returns relative to broader market benchmarks....
Read MoreIs TransMedics Group, Inc. technically bullish or bearish?
2025-11-05 11:23:48As of 31 October 2025, the technical trend for TransMedics Group, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, supporting the positive trend. Daily moving averages also indicate a bullish stance. However, the KST shows a mildly bearish signal on both weekly and monthly time frames, which slightly tempers the overall bullish outlook. The Bollinger Bands are mildly bullish on both weekly and monthly charts. Despite a recent decline in price, the stock has demonstrated strong performance over longer periods, with a year-to-date return of 96.01% compared to the S&P 500's 16.30%, and a five-year return of 870.69% versus the S&P 500's 109.18%. Overall, the current technical stance is bullish, albeit with some mixed signals from the KST....
Read MoreIs TransMedics Group, Inc. technically bullish or bearish?
2025-11-04 11:35:36As of 31 October 2025, the technical trend for TransMedics Group, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance in both time frames. The daily moving averages are bullish, indicating positive momentum. However, the KST and Dow Theory show mildly bearish signals on the weekly and monthly charts, suggesting some caution. In terms of performance, the stock has outperformed the S&P 500 significantly over multiple periods, with a year-to-date return of 100.03% compared to the S&P 500's 16.30%, and a 5-year return of 890.63% versus 109.18%. Overall, the current technical stance is bullish, albeit with some mixed signals in the longer-term indicators....
Read MoreIs TransMedics Group, Inc. technically bullish or bearish?
2025-11-03 11:35:22As of 31 October 2025, the technical trend for TransMedics Group, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate bullish momentum on both time frames. Daily moving averages are bullish as well. However, the KST and Dow Theory show mildly bearish signals on the monthly time frame, suggesting some caution. In terms of performance, TransMedics has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 110.97% compared to the S&P 500's 16.30%. Overall, the strength of the bullish trend is reinforced by the positive technical indicators, despite some mixed signals in the longer-term analysis....
Read MoreIs TransMedics Group, Inc. technically bullish or bearish?
2025-11-02 11:19:27As of 31 October 2025, the technical trend for TransMedics Group, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and both Bollinger Bands are also showing bullish signals. The daily moving averages confirm a bullish stance. However, the KST and Dow Theory indicators are mildly bearish on both weekly and monthly time frames, indicating some caution. The stock has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 110.97% compared to the S&P 500's 16.30%. Overall, the current technical stance is bullish, with strong indicators supporting this view....
Read MoreIs TransMedics Group, Inc. overvalued or undervalued?
2025-10-21 12:11:51As of 17 October 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key valuation ratios include a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22. In comparison to peers, TransMedics has a P/E ratio of 50.23, which is more favorable than iRhythm Technologies, Inc. with a P/E of -111.60, but less favorable than Integer Holdings Corp. at 41.17. The company has shown strong performance with a year-to-date return of 88.66%, significantly outperforming the S&P 500's return of 13.30% over the same period, reinforcing its valuation narrative....
Read MoreIs TransMedics Group, Inc. overvalued or undervalued?
2025-10-20 12:29:07As of 17 October 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 96, an EV to EBITDA of 66.22, and a PEG ratio of 0.53, which suggests a more favorable growth outlook relative to its price. In comparison to peers, TransMedics has a P/E of 50.23, while Integer Holdings Corp. is considered very expensive at a P/E of 41.17, and CONMED Corp. is attractive with a P/E of 19.96. Notably, TransMedics has outperformed the S&P 500 significantly over the 3-year and 5-year periods, with returns of 189.30% and 770.04%, respectively, reinforcing its fair valuation amidst a volatile market....
Read More
Announcement
Corporate ActionsCorporate Actions
